Quick Answer:
Healthcare hospital valuation in India relies on a combination of EV/EBITDA multiples (typically 12x–22x for established chains), revenue-per-bed analysis, and DCF projections adjusted for occupancy rates, case-mix complexity, and regulatory compliance. Under Section 247 of the Companies Act, 2013, valuations for statutory purposes must be conducted by an IBBI Registered Valuer. At Virtual Auditor, we have valued multi-speciality hospitals, single-speciality chains, and diagnostic platforms across 14+ years of practice — applying 18 methods with 10,000 Monte Carlo simulations for defensible, regulator-ready reports.
Definition — Healthcare Valuation: The process of estimating the fair market value or fair value of a hospital, clinic, diagnostic chain, or healthcare services company by analysing clinical capacity, financial performance, regulatory licences, and intangible assets such as brand reputation, doctor networks, and NABH accreditation status.
Definition — Revenue Per Occupied Bed (RPOB): A key performance indicator in hospital valuation, computed as total inpatient revenue divided by the number of occupied bed-days in a given period. RPOB captures both pricing power and case-mix sophistication, making it a superior metric to simple bed-count analysis.
India’s healthcare sector is projected to reach USD 372 billion by 2027, growing at a CAGR of approximately 15–16%. This explosive growth, combined with a complex regulatory environment spanning the Clinical Establishments (Registration and Regulation) Act, 2010, state-level health regulations, and NABH accreditation standards, makes healthcare valuation fundamentally different from valuing a typical services business.
At our business valuation practice, we have observed that generic valuation approaches often fail for hospitals because they ignore:
When a hospital company undergoes mergers, demergers, share allotments under Section 62, or any transaction requiring statutory valuation, Section 247 mandates appointment of a Registered Valuer. The valuer must be registered with the Insolvency and Bankruptcy Board of India (IBBI) under the Companies (Registered Valuers and Valuation) Rules, 2017.
Our registration — IBBI/RV/03/2019/12333 — covers the “Securities or Financial Assets” class, which is the relevant category for valuing equity shares, enterprise value, and financial instruments of healthcare entities.
The IBBI Regulations require valuers to:
This central legislation (adopted by most states) requires every clinical establishment to be registered and meet minimum standards. From a valuation perspective, the Act impacts value in several ways:
The National Accreditation Board for Hospitals & Healthcare Providers (NABH), a constituent board of the Quality Council of India, provides accreditation that significantly impacts hospital valuation:
The most widely used method in healthcare M&A transactions. Comparable transaction and trading multiples for Indian hospitals typically fall in these ranges:
| Hospital Category | EV/EBITDA Range | Key Drivers |
|---|---|---|
| Large multi-speciality chains (500+ beds, multi-city) | 18x – 25x | Brand, scalability, NABH, medical tourism |
| Mid-size multi-speciality (100–500 beds) | 12x – 18x | Occupancy, location, doctor retention |
| Single-speciality chains (eye, dental, ortho, fertility) | 15x – 22x | Scalability, protocol standardisation, lower capex |
| Diagnostic chains (pathology, radiology) | 20x – 30x | Asset-light, hub-and-spoke, sample volumes |
| Standalone single-hospital (sub-100 beds) | 6x – 12x | Doctor-dependency, limited growth, location |
When applying comparable multiples, we adjust for differences in occupancy rates, ARPOB (Average Revenue Per Occupied Bed), payor mix (insurance vs. out-of-pocket vs. government), and geographic concentration risk. Our valuation methodology articles explain how we calibrate multiples using regression analysis on comparable sets.
DCF remains the gold standard for established hospitals with predictable cash flows. Our approach involves:
For a deeper understanding of our DCF methodology, refer to our article on Rule 11UA valuation in India.
This method values a hospital based on the replacement or transaction value per operational bed. It is particularly useful for:
Indicative ranges for enterprise value per bed in India:
For hospitals with significant real estate holdings (owned land and building), the NAV method provides a valuation floor. We engage independent property valuers registered under IBBI for immovable property and add:
Large healthcare groups that operate hospitals, pharmacies, diagnostics, and health-tech platforms require an SOTP approach. Each business vertical is valued using the most appropriate method:
In every healthcare valuation engagement, we deep-dive into the following operational and financial KPIs:
India’s healthcare sector growth is driven by several structural tailwinds:
When modelling growth in a DCF, we differentiate between same-store growth (ARPOB increase, occupancy ramp-up) and new-store growth (bed additions, new locations). Our startup valuation practice applies similar stage-gated modelling for health-tech companies at early stages.
A hospital operating from owned land and building has a fundamentally different risk-return profile from one on a long-term lease. In our valuations, we:
In many Indian hospitals, 20–30% of revenue may be attributable to 2–3 star doctors. We assess:
Hospitals face unique contingent liability risks:
Hospitals empanelled under Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) face reimbursement rates that are typically 30–50% below market rates. While this increases patient volume, it compresses margins. In our valuation, we separately model the government scheme revenue at appropriate margins and assess the risk of rate revisions, delayed reimbursements, and de-empanelment.
Diagnostic companies (pathology and radiology) are valued at premium multiples (20x–30x EV/EBITDA) due to their asset-light hub-and-spoke model, high operating leverage, and scalability. Key metrics include sample volumes, test-per-patient ratio, and revenue per test. The valuation must account for technology risk (automation, AI-based diagnostics) and competition from hospital captive labs.
Eye care (Aravind, Dr. Agarwals, Centre for Sight), dental (Clove Dental), fertility (Indira IVF, Nova IVF), and dermatology chains are valued at premium multiples because of protocol standardisation, lower doctor-dependency, and rapid scalability. Our valuation emphasises unit economics per centre, new centre ramp-up curves, and geographic saturation analysis.
For health-tech companies (online pharmacy, teleconsultation, health records), we apply revenue multiples (3x–10x EV/Revenue) adjusted for unit economics, customer acquisition cost, and retention metrics. Refer to our article on SaaS valuation for comparable methodologies applied to health-tech platforms.
At Virtual Auditor, our healthcare valuation engagement follows a structured workflow:
Engagement pricing for healthcare valuations starts at INR 1,50,000 for standalone hospitals, scaling based on complexity. Visit our pricing page for detailed fee structures.
Practitioner Insight — CA V. Viswanathan
In my 14+ years of valuation practice, I have found that the single biggest mistake in hospital valuation is treating EBITDA as a stable number. Hospital EBITDA is highly sensitive to occupancy — a 5-percentage-point drop in occupancy can reduce EBITDA by 15–20% because of the high fixed-cost base (rent, salaries, equipment depreciation). I always stress-test the valuation at 50%, 60%, and 70% occupancy levels and present the range to the client. Additionally, many acquirers overlook the regulatory renewal risk — we have seen transactions where the target hospital’s Clinical Establishments Act registration was due for renewal with pending compliance issues, which could have wiped out significant value. At Virtual Auditor, every healthcare valuation includes a dedicated regulatory risk section that maps each licence, its expiry, compliance status, and the cost of remediation.
Key Takeaways
Q: What is the typical EV/EBITDA multiple for an Indian hospital?
A: EV/EBITDA multiples for Indian hospitals range from 6x–12x for standalone single-hospital operations to 18x–25x for large multi-speciality chains with NABH accreditation, multiple locations, and strong brand equity. Diagnostic chains command even higher multiples at 20x–30x due to their asset-light, scalable business model. The multiple depends heavily on occupancy rate, ARPOB, geographic diversification, and doctor-dependency risk. Contact our valuation team for a customised comparable analysis.
Q: How does NABH accreditation impact hospital valuation?
A: NABH accreditation impacts valuation through three channels: (1) revenue uplift of 10–20% via higher insurance reimbursement rates and patient willingness to pay, (2) expanded addressable market through eligibility for government schemes and corporate empanelment, and (3) multiple expansion of 2x–4x in EV/EBITDA compared to non-accredited peers. The accreditation also signals operational maturity and reduces clinical risk, which lowers the discount rate applied in DCF valuations.
Q: Who can issue a valuation report for a hospital company under the Companies Act?
A: Under Section 247 of the Companies Act, 2013, valuation for statutory purposes (mergers, demergers, share allotments) must be conducted by a Registered Valuer registered with IBBI. The valuer must hold registration in the “Securities or Financial Assets” class for equity/enterprise valuation, or “Plant and Machinery” / “Land and Building” class for specific asset valuations. CA V. Viswanathan holds IBBI registration IBBI/RV/03/2019/12333 in the Securities or Financial Assets category.
Q: What is revenue per bed and how is it used in hospital valuation?
A: Revenue per bed (or more precisely, Average Revenue Per Occupied Bed — ARPOB) is computed as total inpatient revenue divided by occupied bed-days. For Tier-1 Indian multi-speciality hospitals, ARPOB typically ranges from INR 30,000 to 50,000 per day. Enterprise Value per bed is a complementary metric used for transaction benchmarking, typically ranging from INR 40 lakh to 1.5 crore per bed depending on city tier and speciality. Both metrics are essential for cross-comparison and sanity-checking DCF-derived valuations.
Q: How is a healthcare company valued under IBC (Insolvency and Bankruptcy Code)?
A: Under IBC, specifically Regulation 35 of the IBBI CIRP Regulations, a Registered Valuer must provide both fair value and liquidation value of the hospital as a going concern and on a piecemeal basis. The fair value assessment considers whether the hospital can continue operations under a resolution plan, while liquidation value factors in fire-sale discounts on medical equipment (typically 40–60% of replacement cost), real estate at distressed market value, and the loss of all intangible value (brand, licences, doctor relationships).
Q: What discount rate (WACC) is appropriate for hospital valuation in India?
A: For established Indian hospitals, the cost of equity typically ranges from 13–17%, derived from a risk-free rate of approximately 7% (10-year G-Sec), equity risk premium of 6–8% (Damodaran emerging market premium), and a beta of 0.7–1.1 based on listed hospital comparables. For smaller, single-location hospitals, we add a size premium and company-specific risk premium, taking the cost of equity to 18–22%. WACC ranges from 11–16% depending on capital structure and debt cost.
Q: How does the Clinical Establishments Act affect hospital valuation?
A: The Clinical Establishments (Registration and Regulation) Act, 2010, affects valuation by creating both regulatory risk and competitive moats. Registration under the Act is mandatory for operating a clinical establishment — failure to register or renew registration can lead to closure, directly impacting going-concern value. Conversely, compliance creates barriers to entry. In states that have adopted rate-capping provisions, the Act can limit revenue growth potential. We factor in regulatory compliance status, licence expiry timelines, and state-specific rate regulations in every hospital valuation.
Virtual Auditor — AI-Powered CA & IBBI Registered Valuer Firm
Valuer: V. VISWANATHAN, FCA, ACS, CFE, IBBI/RV/03/2019/12333
Chennai (HQ): G-131, Phase III, Spencer Plaza, Anna Salai, Chennai 600002
Bangalore: 7th Floor, Mahalakshmi Chambers, 29, MG Road, Bangalore 560001
Mumbai: Workafella, Goregaon West, Mumbai 400062
Phone: +91 99622 60333 | Email: support@virtualauditor.in
Book a Consultation